Duality Advisers, LP Neurocrine Biosciences Inc Transaction History

Duality Advisers, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Jun 27, 2023	BUY	$94.11 - $123.02 $1.96 Million - $2.56 Million	20,844 New	20,844 $2.11 Million
Q2 2022 Aug 08, 2022	SELL	$75.79 - $100.07 $585,780 - $773,441	-7,729 Closed	0 $0
Q1 2022 May 09, 2022	SELL	$72.45 - $94.81 $240,461 - $314,674	-3,319 Reduced 30.04%	7,729 $725,000
Q4 2021 Feb 02, 2022	BUY	$79.65 - $106.22 $879,973 - $1.17 Million	11,048 New	11,048 $941,000
Q2 2021 Aug 09, 2021	SELL	$89.43 - $102.27 $301,557 - $344,854	-3,372 Closed	0 $0
Q1 2021 May 13, 2021	SELL	$87.57 - $119.4 $693,554 - $945,648	-7,920 Reduced 70.14%	3,372 $328,000
Q4 2020 Feb 09, 2021	SELL	$86.91 - $108.33 $466,532 - $581,515	-5,368 Reduced 32.22%	11,292 $1.08 Million
Q3 2020 Nov 12, 2020	BUY	$96.16 - $135.15 $1.6 Million - $2.25 Million	16,660 New	16,660 $1.6 Million

635

93.5M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $14.1B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Duality Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Duality Advisers, LP with notifications on news.